RHS Financial LLC Has $542,000 Stock Holdings in Exelixis, Inc. $EXEL

RHS Financial LLC increased its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 4.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,297 shares of the biotechnology company’s stock after acquiring an additional 519 shares during the quarter. RHS Financial LLC’s holdings in Exelixis were worth $542,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in EXEL. Park Avenue Securities LLC increased its holdings in Exelixis by 10.6% in the first quarter. Park Avenue Securities LLC now owns 7,358 shares of the biotechnology company’s stock valued at $272,000 after purchasing an additional 707 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in Exelixis by 6.1% in the first quarter. Farther Finance Advisors LLC now owns 5,372 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 307 shares during the last quarter. GAMMA Investing LLC increased its holdings in Exelixis by 32.2% in the first quarter. GAMMA Investing LLC now owns 5,457 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 1,328 shares during the last quarter. Fifth Third Bancorp increased its holdings in Exelixis by 24.1% in the first quarter. Fifth Third Bancorp now owns 4,011 shares of the biotechnology company’s stock valued at $148,000 after purchasing an additional 780 shares during the last quarter. Finally, NorthCrest Asset Manangement LLC increased its holdings in Exelixis by 66.3% in the first quarter. NorthCrest Asset Manangement LLC now owns 22,505 shares of the biotechnology company’s stock valued at $831,000 after purchasing an additional 8,969 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Price Performance

EXEL stock opened at $38.15 on Monday. The stock has a market capitalization of $10.27 billion, a P/E ratio of 18.34, a P/E/G ratio of 0.76 and a beta of 0.38. The business has a 50-day moving average of $38.63 and a 200-day moving average of $39.95. Exelixis, Inc. has a fifty-two week low of $25.76 and a fifty-two week high of $49.62.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.12. The company had revenue of $568.26 million during the quarter, compared to analysts’ expectations of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.Exelixis’s revenue for the quarter was down 10.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS. Equities analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on EXEL shares. Guggenheim reiterated a “buy” rating and issued a $45.00 price objective on shares of Exelixis in a report on Tuesday, July 29th. Morgan Stanley increased their price target on Exelixis from $46.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, September 17th. Royal Bank Of Canada lowered their price target on Exelixis from $50.00 to $45.00 and set a “sector perform” rating for the company in a report on Tuesday, July 29th. Jefferies Financial Group set a $50.00 price target on Exelixis and gave the stock a “buy” rating in a report on Tuesday, June 24th. Finally, JMP Securities restated a “market outperform” rating and issued a $50.00 price target on shares of Exelixis in a report on Tuesday, July 29th. Fifteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $44.42.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.